The Silicon Review
Anyone who has ever suffered from a debilitating disease knows how difficult it is to get back on track with their lives and careers. Modern medicine and advanced surgical methods have managed to find a cure for diseases that would have meant certain death for the unfortunate patients as recently as 50 years ago. However, the same is not true for neurological diseases. Diseases such as Parkinson’s disease, Alzheimer’s disease, paralysis, dementia, stroke, etc. are caused by a continuing degeneration in the nervous system and make life extremely difficult for the patients as well as their friends and family. Such disorders severely limit activity and the victim becomes completely dependent on nursing care.
A company named Moleac is expanding the horizons in the understanding of neurodegenerative disorders. At Moleac, a team of highly dedicated professionals works tirelessly to find ways to improve the lives of the victims of crippling diseases. By integrating pioneering research and a common vision to alleviate the suffering of victims, Moleac has established itself as a leading center for care and treatment of patients of neurological diseases.
A multi-pronged approach to treatment
Advances in research in the field of brain injury, including stroke, trauma, and global ischemia, have never been more exciting and encouraging to identify novel effective treatments. Neuroscientists have elucidated cellular and molecular mechanisms involved in damages and neurorepair, representing attractive targets to reduce the extent of damage and to enhance remodeling.
Unraveling the complexity of strokes
Stroke is a complex pathology. Treatment encompasses prevention, acute cares, and recovery. While several therapeutic strategies are available to prevent the occurrence of a secondary ischemic episode, acute therapeutic possibilities are limited to revascularization and rehabilitation management. Thus health professionals are facing a therapeutic gap regarding post-stroke recovery. The conventional approach was to develop one molecule to target one specific process in the pathway of one particular disease. This approach was hampered by consecutive failures of multiple clinical trials to prove benefits of potential treatments. With NeuroAiD™, Moleac took a different approach. It takes on a multi-modal approach for drug development. This approach increases the possibility of supporting and enhancing multiple natural processes taking place inside the brain and representing its ability to protect itselfand recover after an injury.
For post-stroke recovery, Moleac has identified a complex formula combining natural ingredients and developed it following international standards of manufacturing and quality control testing. NeuroAiD™ has shown properties of neuroprotection and neuroplasticity affecting multiple pharmacological pathways in rodent models, and animal/human cells cultures. Clinical trials in post-stroke patients have confirmed NeuroAiD™ properties and established its safety and efficacy in stroke survivors by improving their chances of achieving functional independence over the long-term through an increased neurological recovery.
Moleac aims to address the unmet needs of patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. The firm selects scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties and make them available internationally.
Involvement of multidisciplinary experts and international teams
Moleac has established partnerships with leading research institutes in Europe, Middle-East, Oceania, and Singapore for both pre-clinical research and clinical trials. Among them the CNRS (National Center of Scientific Research) in France conducted the pre-clinical research by world-renowned pharmacologists, Prof. Michel Lazdunski, founder of the IPMC (Molecular and Cellular Pharmacological Institute) in Nice Sophia-Antipolis and Dr. Catherine Heurteaux drove the development of innovative therapeutic strategies for the treatment of depression and stroke.
Clinical research was conducted in over 20 centers mainly in South East Asia. The CHIMES / CHIMES-E trial recruited 1100 patients from Singapore, Philippines, Thailand, Sri Lanka, Hong Kong, and Malaysia. The CHIMES / CHIMES-E trial represent the main trial conducted on NeuroAiD™ and are also the first clinical trial on post-stroke recovery providing long-term follow-up, up to two years after stroke onset. An important number of internationally renowned Key Opinion Leaders including Prof. G Donnan (Australia), and Prof. C Chen (Singapore) were also independently conducting these clinical programmes. This multi-disciplinary and international team with its capabilities and credentials is the key to successfully drive the clinical trial with NeuroAiD™. Moleac has to its credit over 30 scientific papers published over the past few years in peer-reviewed international journals such as Stroke, Cerebrovascular Diseases, European Neurology and Neuropharmacology. Most of the new findings were presented in international conferences on stroke (European Stroke Conference, European Stroke Organization Conference, Asia Pacific Stroke Conference, and so on).
Meet the visionary behind Moleac, David Picard
David co-founded Moleac and has been serving as CEO since. Prior to founding Moleac, David has spent ten years at the Boston Consulting Group (“BCG”) where he was a member of the worldwide Health Care Practice Area. He has worked both in Europe and in Asia. He has extensive experience in working in China and in Korea.
David graduated from the two top engineering schools in France, EcolePolytechnique, and EcoleNationaleSupérieure des Mines de Paris, where he majored in mathematics and economics. David also holds a French degree (“DESS”) in business law.